Key facts
- This page summarizes Katherine Beebe DeVarney's Form 4 filing for TITAN PHARMACEUTICALS INC (TTNP).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 28 Jul 2023, 17:45.
Katherine Beebe DeVarney - 26 Jul 2023 Form 4 Insider Report for TITAN PHARMACEUTICALS INC (TTNP)
- Reporting relationship
- President and COO, Director
- Issuer ticker
- TTNP
- Reported as of
- 26 Jul 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 28 Jul 2023, 17:45:40 UTC
- Prior SEC filing
- 05 Jan 2022
- Next SEC filing
- 26 Oct 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Katherine Beebe DeVarney
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Katherine Beebe DeVarney filed Form 4 for TITAN PHARMACEUTICALS INC (TTNP) on 28 Jul 2023.
Change
- Previous filing in this sequence was filed on 05 Jan 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
TTNP
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +50,000
- Change %
- Price
- $0.000000
- Shares after
- 50,000
- Date
- 26 Jul 2023
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
TTNP
transaction
Derivative
Option to Purchase Common Stock
Award
- Transaction value
- $0
- Shares
- +100,000
- Change %
- Price
- $0.000000
- Shares after
- 100,000
- Date
- 29 Jun 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 100,000
- Exercise price
- $1.31
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The shares reported in this transaction represent Unrestricted Stock Awards pursuant to the Issuer's Fourth Amended and Restated 2015 Omnibus Equity Incentive Plan that vested immediately on the date of grant.
Footnote F2
The options were approved by the Issuer's Board of Directors on August 15, 2022. The options were conditioned on the approval by the Issuer's stockholders of an increase in the number of shares available for issuance under the 2015 Omnibus Equity Incentive Plan, which approval occurred on June 29, 2023. The exercise price of the options is equal to the closing price of the Issuer's common stock on August 15, 2022.